EMEA-003378-PIP01-23 - paediatric investigation plan

ivonescimab

Key facts

• Active substance:
  ivonescimab
• Therapeutic area:
  Oncology
• Decision number:
  P/0342/2023
• PIP number:
  EMEA-003378-PIP01-23
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of lung cancer
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  08/09/2023
• Compliance check done:
  No

Decision

P/0342/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for ivonescimab (EMEA-003378-PIP01-23)

Adopted Reference Number: EMA/352005/2023